Trials for new weight loss drug begin in Bradford
6 hours ago


Bradford Teaching Hospitals NHS Trust
Researchers developing a new weight loss drug are looking for people to take part in clinical trials in Bradford
The GLP-1 drug – similar to medications such as Wegovy and Mounjaro – is being trialled at Bradford Teaching Hospitals NHS Trust to see if it helps people lose weight, lower blood sugar and improve overall health
The trials are taking place as part of a project in which NHS centres are used, and paid, to carry out clinical trials for pharmacy companies
Chief investigator Steven Lindsay said the medication, which would be taken as a weekly injection, could be more effective and have fewer side effects than those already available
GLP-1s are medicines that help people feel fuller by mimicking a natural hormone released after eating
In the UK, there are currently several licensed GLP-1 medicines – including Wegovy, Ozempic and Mounjaro – but they are prescription-only
“It’s relatively difficult to get these drugs through primary care in the current climate so people are sourcing them through private providers, and there’s always a potential issue there about that sort of pathway,” explained Lindsay
He said one of the issues with non-prescription weight loss drugs was that patients did not receive the holistic care they required
“You lose weight because you don’t eat as much but if you eat the wrong stuff and you’re not eating very much, you don’t get enough protein in, then you end up losing muscle mass
“And there’s evidence of groups of patients ending up with an assortment of nutritional deficiencies as a consequence of taking a tablet that stops them eating and then just not eating enough of the right stuff.”
But if the trial was successful it could mean more availability of approved weight loss drugs, he said
‘Get ahead of the game’
Bradford Teaching Hospitals is inviting people over 18 who are obese or overweight and have at least one weight-related health condition to take part
The Bradford trials are just one of many ongoing internationally, as the company behind the drug is Chinese but run from the US, Lindsay said
It is hoped inviting patients from across Bradford will widen the demographic of people participating, which was important, he said, as women and ethnic minorities were often under-represented in medical trials
“We’re working very hard at trying to increase recruitment from those groups because ideally you want studies that demonstrate benefit across all the groups that you want to treat,” he said
“Anyone who’s interested in getting involved in research – it’s a good thing to do because you get access to things that aren’t there yet. So you get ahead of the game.”
Listen to highlights fromWest Yorkshire on BBC Sounds, catch up with the latestepisode of Look North
Weight loss jab users hope pills could cut cost
From mouthwash to hair dye: How weight-loss jabs are changing shopping habits
Ozempic-maker accuses rival of false advertising
NHS
Obesity
Weight loss
Bradford


